Business
NurExone Expands European Engagement with Investor Events in Germany and Switzerland
TORONTO and HAIFA, Israel, May 02, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (O...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Expands European Engagement with Investor Events in Germany and Switzerland\n\n\n\n TORONTO and HAIFA, Israel, May 02, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“\n \n NurExone\n \n ” or the “\n \n Company\n \n ”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is deepening its engagement with the European financial and healthcare communities through participation in three upcoming events. This increased activity follows NurExone’s recent announcement of a potential\n \n third therapeutic indication\n \n for its lead drug asset, ExoPTEN – underscoring the Company’s momentum and expansion within the biotechnology sector.\n \n\n CEO Dr. Lior Shaltiel will represent NurExone at INVEST 2025 in Stuttgart, a leading investment conference for German-speaking markets including Germany, Austria, and Switzerland. The conference provides a platform for NurExone to present its corporate strategy, pipeline development, and the latest progress with ExoPTEN to an influential audience of institutional and private investors. The initiative is being actively supported by Dr. Eva Reuter, who leads NurExone’s investor relations efforts in Germany.\n \n\n “Our participation in INVEST 2025 reflects NurExone’s growing commitment to the European investment community, particularly our expanding German-speaking investor base,” said Dr. Lior Shaltiel, CEO of NurExone. “We are building long-term relationships with stakeholders who share our vision for the transformative potential of exosome-based therapeutics.”\n \n\n NurExone has also been selected to participate in the Healthtech Roadshow, taking place in Zurich from May 5-8, 2025. Organized by the Israel Export Institute, the roadshow offers targeted engagement with healthcare professionals and life science investors in Switzerland.\n \n\n A week later, from May 12-15, 2025 at\n \n BioProcess International Europe\n \n in Hamburg, Dr. Shaltiel will deliver a featured presentation entitled “\n \n Transforming Spinal Cord Injury Treatment: NurExone's Groundbreaking Exosome-Based siRNA Therapy and Expanding Pipeline for Neuronal Regeneration.\n \n ” He will also take part in a panel di...